Protagonist Therapeutics Inc expected to post a loss of 63  cents a share - Earnings Preview

Protagonist Therapeutics

29/04/2022 15:51

* Protagonist Therapeutics Inc  PTGX.OQ   PTGX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 2 (estimated). 
    * The Newark California California-based  company is
expected to
report  a 175.5% increase in revenue to $17.05 million from
$6.19 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Protagonist
Therapeutics
Inc is for a loss of 63 cents per share. For the same quarter
last year, the company reported a loss of 54 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $50​, above​ its last closing price
of $9.08. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.81       -0.78      -0.77     Beat    1.6
 Sep. 30 2021  -0.69       -0.67      -0.70     Missed  -4.5
 Jun. 30 2021  -0.54       -0.55      -0.69     Missed  -26.1​
 Mar. 31 2021  -0.56       -0.57      -0.54     Beat    4.9
 ​​Dec.        -0.50       -0.48      -0.48     Met     -0.4
 31 2020                                                
 Sep. 30 2020  -0.61       -0.61      -0.21     Beat    65.7​
 Jun. 30 2020  -0.58       -0.59      -0.61     Missed  -2.5
 Mar. 31 2020  -0.69       -0.69      -0.72     Missed  -4
 This summary was machine generated April 29 at 14:51 GMT.  All
figures in US dollars  unless otherwise stated